Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer by Bolton, Kelly L et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Association between BRCA1 and BRCA2 mutations and survival
in women with invasive epithelial ovarian cancer
Citation for published version:
Bolton, KL, Chenevix-Trench, G, Goh, C, Sadetzki, S, Ramus, SJ, Karlan, BY, Lambrechts, D, Despierre, E,
Barrowdale, D, McGuffog, L, Healey, S, Easton, DF, Sinilnikova, O, Benítez, J, García, MJ, Neuhausen, S,
Gail, MH, Hartge, P, Peock, S, Frost, D, Evans, DG, Eeles, R, Godwin, AK, Daly, MB, Kwong, A, Ma, ESK,
Lázaro, C, Blanco, I, Montagna, M, D'Andrea, E, Nicoletto, MO, Johnatty, SE, Kjær, SK, Jensen, A, Høgdall,
E, Goode, EL, Fridley, BL, Loud, JT, Greene, MH, Mai, PL, Chetrit, A, Lubin, F, Hirsh-Yechezkel, G,
Glendon, G, Andrulis, IL, Toland, AE, Senter, L, Gore, ME, Gourley, C, Michie, CO & EMBRACE 2012,
'Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian
cancer'  JAMA: the Journal of the American Medical Association, vol. 307, no. 4, pp. 382-90. DOI:
10.1001/jama.2012.20
Digital Object Identifier (DOI):
10.1001/jama.2012.20
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
 JAMA: the Journal of the American Medical Association
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Association Between BRCA1 and BRCA2 Mutations and Survival
in Women with Invasive Epithelial Ovarian Cancer
Kelly L. Bolton1,2, Georgia Chenevix-Trench3, Cindy Goh4, Siegal Sadetzki5,6, Susan J.
Ramus7, Beth Y. Karlan8, Diether Lambrechts9, Evelyn Despierre10, Daniel Barrowdale11,
Lesley McGuffog11, Sue Healey3, Douglas F. Easton11, Olga Sinilnikova12,13, Javier
Benitez14,15, María J. García15,16, Susan Neuhausen17, Mitchell H. Gail1, Patricia Hartge1,
EMBRACE study team11, Susan Peock11, Debra Frost11, D. Gareth Evans18, Ros Eeles19,
Andrew K. Godwin20, Mary B. Daly21, Ava Kwong22,23, Edmond SK Ma22,24, Conxi Lázaro25,
Ignacio Blanco25, Marco Montagna26, Emma D’Andrea27,28, Ornella Nicoletto29, kConFab
Investigators30, Sharon E. Johnatty3, Susanne Krüger Kjær31,32, Allan Jensen31,32, Estrid
Høgdall31,32, Ellen L. Goode33, Brooke L. Fridley33, Jennifer T. Loud34, Mark H. Greene34,
Phuong L. Mai34, Angela Chetrit5, Flora Lubin35, Galit Hirsh-Yechezkel5, Gord Glendon36,
Irene L. Andrulis36,37, Amanda E. Toland38, Leigha Senter39, Martin E. Gore40, Charlie
Gourley41, Caroline O Michie41, Honglin Song42, Jonathan Tyrer42, Alice S. Whittemore43,
Valerie McGuire43, Weiva Sieh43, Ulf Kristoffersson44, Håkan Olsson45, Åke Borg45,
Douglas A. Levine46, Cancer Genome Atlas Research Network47, Linda Steele17, Mary S.
Beattie48,49, Salina Chan48, Robert Nussbaum48,49, Kirsten B. Moysich50, Jenny Gross8,
Ilana Cass8, Christine Walsh8, Andrew J. Li8, Ronald Leuchter8, Ora Gordon8, Montserrat
Garcia-Closas51, Simon A. Gayther7, Stephen J. Chanock1, Antonis C. Antoniou11, and
Paul D.P. Pharoah42
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda MD 20892,
USA
2David Geffen School of Medicine at the University of California, Los Angeles CA 90095, USA
3Queensland Institute of Medical Research, Locked Bag 2000, Royal Brisbane Hospital, Herston,
QLD 4029, Australia
4Addenbrooke’s Hospital, Hills Road, Cambridge CB2 OQQ, UK
5Cancer and Radiation Epidemiology Unit, Gertner Institute for Epidemiology and Health Policy,
Sheba Medical Center, Tel Hashomer, 52621, Israel
6Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, 69978 Israel
7Department of Preventive Medicine, Keck School of Medicine University of Southern California,
Los Angeles, California, 90033, USA
8Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Medical Center, Los Angeles, CA, 90048 USA
9VIB Vesalius Research Center, University of Leuven, Leuven, 3000 Belgium
10Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, University
Hospitals Leuven, University of Leuven, Leuven, 3000 Belgium
Access to data
Kelly Leigh Bolton had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of
the data analysis.
NIH Public Access
Author Manuscript
JAMA. Author manuscript; available in PMC 2013 July 30.
Published in final edited form as:
JAMA. 2012 January 25; 307(4): 382–390. doi:10.1001/jama.2012.20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
11Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care,
University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1
8RN, UK
12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Centre Hospitalier
Universitaire de Lyon, Lyon 69373, France
13Centre Léon Bérard, and Equipe labellisée LIGUE 2008, UMR5201 CNRS, Centre Léon Bérard,
Université de Lyon, Lyon 69373, France
14Human Cancer Genetics Programme and Genotyping Unit, Spanish National Cancer Research
Centre, Melchor Fernández Almagro 3, Madrid 28029, Spain
15CIBERER, Melchor Fernández Almagro 3, Madrid 28029, Spain
16Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer
Research Centre, Melchor Fernández Almagro 3, Madrid 28029, Spain
17Department of Population Sciences, the Beckman Research Institute of the City of Hope,
Duarte, CA 91010, USA
18Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester
University Hospitals NHS Foundation Trust, Manchester, M13 9WL UK
19Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation
Trust, SM2 5NG UK
20Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center,
Kansas City, KS 66160, USA
21Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
22The Hong Kong Hereditary Breast Cancer Family Registry, Cancer Genetics Centre, Hong
Kong Sanatorium and Hospital, 4/F, Central Block, 2 Village Road, Hong Kong
23Division of Breast Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong
24Division of Molecular Pathology, Hong Kong Sanatorium and Hospital, 4/F, Central Block, 2
Village Road, Hong Kong
25Hereditary Cancer Programme, Catalan Institute of Oncology, IDIBELL, Gran Via 199-203,
L’Hospitalet, Barcelona 08907, Spain
26Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto - IRCCS, Via
Gattamelata 64, 35128 Padua, Italy
27Department of Oncology and Surgical Sciences, University of Padua, 35128 Padua, Italy
28Istituto Oncologico Veneto IRCCS, Via Gattamelata 64, 35128 Padua, Italy
29Medical Oncology Unit, Istituto Oncologico Veneto - IRCCS, Via Gattamelata 64, 35128 Padua,
Italy
30Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
31Department of Virus, Hormones and Cancer, Danish Cancer Society, Copenhagen, 2100
Denmark
32Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, 2100
Denmark
33Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester,
Minnesota 55905, USA
Bolton et al. Page 2
JAMA. Author manuscript; available in PMC 2013 July 30.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
34Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer
Institute, Rockville MD 20852, USA
35Gertner Institute for Epidemiology and Health Policy, Sheba Medical Center, Tel Hashomer,
52621, Israel
36Ontario Cancer Genetics Network, Cancer Care Ontario, Toronto, Ontario, M5G 2C1 Canada
37Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5
Canada
38Division of Human Cancer Genetics, Departments of Internal Medicine and Molecular Virology,
Immunology and Medical Genetics, The Comprehensive Cancer Center, The Ohio State
University, Columbus, USA
39Clinical Cancer Genetics Program, Division of Human Genetics, Department of Internal
Medicine, The Comprehensive Cancer Center, The Ohio State University, Columbus, 43210 USA
40Gynecological Oncology Unit, The Royal Marsden Hospital, FulhamRoad, London SW3 6JJ, UK
41University of Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine,
Western General Hospital, Edinburgh, EH4 2XR UK
42Cancer Research United Kingdom, Department of Oncology and Department of Public Health
and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts
Causeway, Cambridge CB1 8RN, UK
43Department of Health Research and Policy, Stanford University School of Medicine, Stanford,
CA 94305, USA
44Department of Clinical Genetics, University and Regional Laboratories Skåne and Lund
University, SE-20502 Lund, Sweden
45Department of Oncology, Lund University, SE-22185 Lund, Sweden
46Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New
York, NY, 10065 USA
47National Cancer Institute at National Institutes of Health, Bethesda, MD 20892, USA
48UCSF Cancer Risk Program, San Fransisco, CA 94143, USA
49UCSF Departments of Medicine, San Fransisco, CA 94118, USA
50Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY
14263, USA
51Sections of Epidemiology and Genetics, Institute of Cancer Research and Breakthrough Breast
Cancer Research Centre, London, SW7 3RP UK
Abstract
Context—Approximately 10 percent of women with invasive epithelial ovarian cancer (EOC)
carry deleterious germline mutations in BRCA1 or BRCA2. A recent report suggested that
BRCA2 related EOC was associated with an improved prognosis, but the effect of BRCA1
remains unclear.
Objective—To characterize the survival of BRCA carriers with EOC compared to non-carriers
and to determine whether BRCA1 and BRCA2 carriers show similar survival patterns.
Design, Setting, and Participants—We pooled data from 26 studies on the survival of
women with ovarian cancer. This included data on 1,213 EOC cases with pathogenic germline
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mutations in BRCA1 (909) or BRCA2 (304) and 2,666 non-carriers recruited and followed for
variable times between 1987 and 2010; the median year of diagnosis was 1998.
Main Outcome Measures—Five year overall mortality.
Results—The five-year overall survival was 36 percent (95% CI: 34–38) for non-carriers, 44
percent (95% CI: 40–48) for BRCA1 carriers and 52 percent (95% CI: 46–58) for BRCA2
carriers. After adjusting for study and year of diagnosis, BRCA1 and BRCA2 carriers showed a
more favorable survival than non-carriers (BRCA1, HR=0.78; 95% CI=0.68–0.89, P=2×10−4;
BRCA2, HR = 0.61; 95% CI=0.50–0.76, P=6×10−6). These survival differences remained after
additional adjustment for stage, grade, histology and age at diagnosis (BRCA1, HR=0.73, 95%
CI=0.64–0.84, P=2×10−5; BRCA2, HR = 0.49, 95% CI=0.39–0.61, P=3×10−10).
Conclusions—Among patients with invasive epithelial ovarian cancer, having a germline
mutation in BRCA1 or BRCA2 was associated with improved 5-year overall survival.
Introduction
Germline mutations in the genes BRCA1 and BRCA2 are the strongest known genetic risk
factors for both breast and epithelial ovarian cancer (EOC) and are found in 6–15 percent of
women with EOC1–3. BRCA1 is involved in DNA repair, cell-cycle checkpoint control,
chromatin remodeling, transcriptional regulation and mitosis and BRCA2 has an important
role in homologous recombination 4. The clinical characteristics of EOCs among BRCA1/2
carriers differ from that of non-carriers. BRCA1 related disease is more likely to be of
serous histology5, high grade6 and advanced stage3. Less data are available for BRCA2-
related EOC due to their lower prevalence and lower EOC penetrance relative to BRCA1
but a similar pattern is generally reported5;7.
The relative prognosis of BRCA1/2 carriers and non-carriers is unclear. A recent report
found a more favorable outcome for BRCA2 mutation carriers, with no significant
difference in outcome for BRCA1 mutation carriers compared to non-carriers8. However,
some studies have demonstrated a more favorable prognosis for BRCA1 and BRCA2
carriers6;7;9 compared to non-carriers whereas others have reported no significant
difference10;11. Several factors may account for these divergent results. Most studies
contained fewer than 50 carriers and all contained fewer than 250 carriers resulting in
imprecise survival estimates. Small sample sizes have also resulted in the grouping of
BRCA1 and BRCA2 carriers together for analysis, despite potential prognostic differences.
In addition, adjustment for prognostic factors known to differ by carrier status has varied
among studies. Finally, few studies employed appropriate statistical methods to account for
the potential bias that results from the inclusion of prevalent cases12. The mechanism
driving the association between BRCA1/2 mutations and survival is not known but some
retrospective studies suggested that the survival advantage of carriers could be mediated
through improved response to platinum-based agents7;13. This is consistent with in vitro
studies showing that BRCA1 and BRCA2 deficient cells are hypersensitive to drugs which
induce double strand DNA breaks such as platinum-based agents14.
The aim of this study was to collate the data from multiple EOC case series with data on
BRCA1 and BRCA2 mutation status in order to provide definitive evidence of the relative
effect of germline BRCA1 and BRCA2 mutations on prognosis. The results could provide
insight into the biology of BRCA1/2 mutations, improve clinical management of mutation
carriers and have implications for clinical trial design, particularly for agents targeting
BRCA1/2 dysfunction such as poly (ADP-ribose)-polymerase (PARP) inhibitors15.
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Methods
Study Design
Study participants were women with confirmed invasive EOC both with and without
pathogenic mutations in BRCA1 and BRCA2. Participants were drawn from 26 studies: 10
from the USA, six from Europe, two from Israel, one from Hong Kong, one from Canada,
one from Australia and five from the UK. Participants were enrolled in clinical research
protocols between 1987 and 2010 that were approved by local institutional review boards.
Written consent was obtained from all living patients. Most participating studies were
affiliated with either the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)16
or the Ovarian Cancer Association Consortium (OCAC)17. Investigators submitted data on
patient demographics, tumor pathology, vital status and treatment to the coordinating group
in Cambridge. In some studies, EOC cases were recruited based on a strong family history
of ovarian and/or breast cancer (family-based), while others used population-based sampling
or enrolled a consecutive series of cases treated at a single or multiple institution(s). In all
studies, BRCA1/2 carriers and non-carriers were enrolled into the study using the same
criteria.
Mutations were considered pathogenic if they met criteria defined by the Breast Cancer
Information Core18;19 and were grouped into categories based on their predicted functional
effect20–23. Women with variants of unknown significance in BRCA1 or BRCA2 were
excluded. Class I mutations are the most frequent and represent loss-of-function mutations
predicted to result in reduced transcript or protein level due to mRNA nonsense-mediated
RNA decay, translational retention or absence of expression. Class II contains those
mutations likely to generate stable proteins that may have some normal or dominant
negative function. This includes missense substitutions and mutations generating a
premature stop codon in the last exon. All participants were screened for both BRCA1 and
BRCA2 mutations with three exceptions. In three family-based studies, the Kathleen
Cuningham Consortium for Research into Familial Breast Cancer, the UK Gilda Radner
Familial Ovarian Cancer Registries and the National Cancer Institute study, some EOC
cases were not tested for BRCA1/2 and BRCA1/2 status was assumed to be same as that of
affected family member(s) who had been tested. The non-carrier group from the RMH study
contained some untested EOC cases but who reported no family history of breast or ovarian
cancer and were therefore considered unlikely to harbor mutations. Finally, in the Stanford
Genetic Epidemiology of Ovarian Cancer study, only BRCA1 mutation testing was
performed. A variety of methods were used to perform mutation testing (eTable 1).
Data on tumor pathology, vital status and treatment were obtained through a combination of
medical records, local cancer registries and death certificates. Infrequently, vital status was
determined through direct contact with a physician or family member of the patient. In a
subset of studies, information regarding residual disease following primary surgery was
available from medical records. Optimal debulking was defined as residual disease =<1cm
and suboptimal debulking as residual disease > 1cm.
BRCA1/2 status may modify response to platinum based chemotherapy which became
standard of care in most countries around 1990. Among the 36 percent of subjects with
chemotherapy data, 95 percent of cases diagnosed after 1990 were reported to have received
a platinum-based agent. We therefore excluded women diagnosed before 1990 if
chemotherapy regime was unknown, and those known not to have received platinum based
chemotherapy.
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Statistical Analysis
The primary endpoint was overall survival (OS) up to five years following EOC diagnosis.
We chose this endpoint in order to minimize the influence of non-EOC related deaths. Time-
to-event (death or censoring) was calculated from the date of diagnosis. However, cases
were recruited at variable times after diagnosis and so time under observation was calculated
from date of recruitment (left truncation) in order to prevent the bias that could result from
the inclusion of prevalent cases. Effect estimates from left-truncated data are considered to
be unbiased if the event time and delayed entry time are independent, given the covariates24.
Differences in tumor stage, grade, histology and age at diagnosis between BRCA1, BRCA2
and non-carriers were tested using logistic regression adjusted for study site. We used Cox
proportional-hazards models to estimate hazard ratios (HR) and 95 percent confidence
intervals (CI). All models were adjusted for year of EOC diagnosis (<1990, 1990–1995,
1996–2000, 2000–2010) and stratified by study site. In stratified survival analyses, strata
with small numbers of deaths can lead to unreliable estimates. For this reason, four studies
with less than 30 cases were placed in the same strata as other studies sharing similar study
designs and baseline survival rates.
We performed analyses with and without adjustment for stage, grade, histology and age at
diagnosis. The proportional hazards assumption was tested for each covariate analytically
using Schoenfeld residuals. Age at diagnosis and histology violated the PH assumption so
additional covariates were included to allow for time-dependent effects
Differences in the HR estimates for the survival impact of BRCA1 and BRCA2 by different
clinical factors were tested using Cochrane’s chi-square test (Q-test) for heterogeneity. To
assess the impact of possible competing mortality from breast cancer on effect estimates, we
compared analyses restricted to women with and without a diagnosis of breast cancer before
or in the five years following EOC diagnosis. We tested for heterogeneity by study in the
HR estimates through the inclusion of an interaction term between study and BRCA1/2
mutation status.
Some participants were missing data for stage (19%), grade (22%) and histology (5%). In
order to decrease potential bias and loss of power due to missingness, we performed
multiple imputation for these three variables (eMethods). All analyses, except for
comparison of pathological characteristics and Kaplan Meier estimation of survival, were
performed on the imputed data. The results using non-imputed data were similar to those
presented here using imputed data; for comparison, the main results using non-imputed data
are presented in eTable 2. All analyses were performed using STATA/SE version 11
(StataCorp, College Station, TX, USA). Statistical significance was defined as a P value of
less than 0.05. Statistical tests were two sided.
Results
Data were available for 3,879 EOC cases; 909 BRCA1 and 304 BRCA2 mutation carriers
and 2,666 non-carriers. The median number of months from ascertainment to diagnosis for
participants was 1 month (25th–75th percentile: 0–15 months). Women were under active
follow-up for a median time of 38 months (25th–75th percentile: 18–77 months). The
proportion of cases with censored survival time (not followed to death or 5 years after
diagnosis) was 15 percent. After controlling for study site, there was no significant
difference in the proportion of cases with censored survival time among BRCA1 (p=0.22) or
BRCA2 (p=0.41) carriers compared to non-carriers. The median year of diagnosis was 1998
(range: 1981–2010). During the five years following EOC diagnosis, 1,766 deaths occurred.
We found several significant differences in the clinical features of BRCA1 and BRCA2
carriers compared to non-carriers (Table 1). Tumors in BRCA1 and BRCA2 carriers were
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more likely to be of serous histology and less likely to be of mucinous histology than tumors
in non-carriers. BRCA1 and BRCA2 carriers were more likely to have stage III/IV tumors
and poorly differentiated/undifferentiated tumors than non-carriers. Compared to BRCA1
carriers, BRCA2 carriers were more likely to have stage III/IV tumors. While BRCA1
carriers were younger at diagnosis than non-carriers, BRCA2 carriers were slightly older.
The five-year overall survival was 36 percent (95% CI: 34–38) for non-carriers, 44 percent
(95% CI: 40–48) for BRCA1 carriers and 52 percent (95% CI: 46–58) for BRCA2 carriers
(Figure 1 and eFigure 1). In a Cox regression model only adjusted for study and year of
diagnosis, BRCA1 carriers showed a more favorable survival than non-carriers (HR=0.78;
95% CI=0.68–0.89; P=2×10−4) (Table 2). This improved slightly after additional adjustment
for stage, grade, histology and age at diagnosis (HR=0.73; 95% CI=0.64–0.84; P=2×10−5).
BRCA2 carriers showed a greater survival advantage compared to non-carriers (HR = 0.61;
95% CI=0.50–0.76, P=6×10−6), particularly after adjusting for other prognostic factors (HR
= 0.49; 95% CI=0.39–0.61, P=3×10−10). The BRCA1 HR estimates were significantly
different from the BRCA2 HR estimates in unadjusted (Phet=0.05) and adjusted models
(Phet=0.003).
We studied the impact of BRCA1/2 mutation status on all-cause mortality after stratifying
patients by other clinical features (Table 3). In analyses stratified by grade and adjusted for
other prognostic factors the HRs were >1 for both BRCA1 vs. non-carriers and BRCA2 vs.
non-carriers in low grade cases but <1 in high grade cases. There were no significant
differences in the HRs for BRCA1 vs. non-carriers or BRCA2 vs. non-carriers when
stratified according to tumor stage, histology or history of breast cancer before or during the
study period. The survival advantage of BRCA1 and BRCA2 carriers compared to non-
carriers was found to be attenuated in women with ovarian cancer selected based on family
history of ovarian and/or breast cancer (Table 4). However, the difference in survival
between BRCA1 and BRCA2 carriers did not depend on ascertainment (HR for BRCA2 vs.
BRCA1: 0.71, 95% CI=0.52–0.98 and 0.64, 95% CI=0.45–0.91 for familial and unselected
cases respectively; Phet=0.65). There was no evidence of study-specific heterogeneity in the
HR estimates for mutation status among family-based studies (BRCA1, p=0.22; BRCA2,
p=0.92) or unselected studies (BRCA1, p=0.73; BRCA2, p=0.57).
The proportion of mutation carriers with the Ashkenazi Jewish founder mutations 185delAG
and 5382insC in BRCA1 and 6174delT in BRCA2 was 26 percent. We did not find any
significant differences in the adjusted HRs for BRCA1 vs. non-carriers among carriers by
mutation type (Class I vs. Class II mutation Phet=0.10). However, the survival advantage of
BRCA1 mutation carriers with Class I mutations differed depending on mutation location;
worse survival was associated with mutations on the 5′ end compared to the 3′ end of
BRCA1 (P=0.03) (eMethods and eTable 3).
A subset of 1129 patients had information on residual disease following primary surgery.
We assessed the impact of lack of adjustment for these variables in our main analysis by
comparing results with and without adjustment for residual disease in this subgroup.
Optimal debulking occurred in 85% of non-carriers, 87% of BRCA1 carriers and 91% of
BRCA2 carriers. After adjusting for study site and year of diagnosis, there was no
significant difference in the likelihood of optimal debulking between non-carriers and
BRCA1 (p=0.74) or BRCA2 (p=0.46) carriers. Adjustment for residual disease did not
substantially change the HR estimates for the relative survival of either BRCA1 or BRCA2
carriers compared to non-carriers (eTable 4).
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Discussion
Our data demonstrate an improved survival in EOC patients with germline BRCA1 and
BRCA2 mutations relative to non-carriers, with BRCA2 carriers having the best prognosis.
BRCA1 carriers presented with EOC at an earlier age than BRCA2 carriers which is
consistent with the age-specific penetrances for BRCA1 compared to BRCA2 carriers. The
pathological characteristics of BRCA1 and BRCA2 related tumors are similar to each other,
but differ from those of tumors in non-carriers. This contrasts with breast cancer, in which
substantial differences between BRCA1 and BRCA2-associated disease are present25;26.
The differences in grade, stage and histology by mutation status are consistent with
previously reported data5;27. The impact of BRCA1 and BRCA2 mutations on survival
appeared to be similar among patients with both localized and advanced stage tumors and
among both serous and non-serous tumors. The lack of a survival advantage for BRCA1 and
BRCA2 mutation carriers with low grade disease suggests that disruptions of the BRCA1/2
pathways may not be as important in the etiology of these tumors, supporting evidence of
etiologic heterogeneity between high grade and low grade serous carcinoma from other
studies28;29. However, these results were based on small numbers and require confirmation
in larger studies.
Our findings confirm the findings of recent analysis of data from the Cancer Genome Atlas
(TCGA) project which reported an improved prognosis for BRCA2 carriers8. In contrast we
also found an improved prognosis for BRCA1 carriers, whereas the TCGA data suggested
no difference between BRCA1 carriers and non-carriers. The most likely reason for this
difference is the lack of power to detect a moderate difference in survival in the TCGA data.
Indeed, the hazard ratio for BRCA1 carriers compared to non-carriers reported by Yang and
colleagues (multivariate adjusted HR=0.76) was very similar to that from our analysis
(multivariate adjusted HR=0.73).
We found a smaller survival effect of BRCA1 and BRCA2 in the subset of studies where
participants selected based on a strong family history of ovarian and/or breast cancer. This
could have been due to misclassification of non-carriers in these studies. The sensitivity of
mutation testing is likely to be similar across all studies but the proportion of false negative
carriers will be higher in familial cases. Alternatively, cases from BRCA1/2 wild-type
families could carry germline mutations in genes in the same pathway as BRCA1/2 (such as
RAD51C30) or in different pathways that produce similar clinical features.
The improved survival of BRCA1/2 carriers relative to non-carriers, and the survival
advantage of BRCA2 carriers relative to BRCA1 carriers could be related to intrinsic
biological differences, their response to therapeutic agents or both. In addition to differences
in stage, grade and histology, BRCA1/2 carriers could have differences in other aspects of
tumor biology that were not measured in the current study. For example, BRCA1 and
BRCA2 carriers have been recently shown to differ from each other and from sporadic EOC
in the incidence of visceral metastasis31.
The most notable advantage as well as disadvantage of our study is the fact that it is based
on a heterogeneous population; these data were taken from studies containing different
ethnic groups, employing different mutation screening methodologies and case
ascertainment. By including a wide variety of studies, we were able to generate a large
enough sample size to adequately address the issue of heterogeneity of the survival effect
between BRCA1 and BRCA2 carriers. But, differences in study design and population may
limit the specificity of the conclusions drawn. Additionally, varying levels of
misclassification of BRCA status and other variables of interest may have led to some bias
of our estimates towards the null. However, the absence of heterogeneity in study-specific
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effects (after accounting for selection on family history) suggests that these results are
generalizable to many populations. Furthermore, the magnitude of the differences we
observed between BRCA1, BRCA2 carriers and non-carriers, despite the presence of
heterogeneity, provide further testament to their robustness. Even at the lower bounds of our
effect estimates, BRCA2 carriers would be predicted to show a 64% decreased risk of death
in the five years following diagnosis compared to non- carriers.
Our findings could have relevance to an even higher proportion of EOC patients if somatic
mutations and epigenetic silencing of BRCA1 and BRCA2 show similar effects on
prognosis to germline mutations. It has been estimated that roughly 30% of EOC and over
half of high-grade serous EOC could show dysfunction of BRCA1 or BRCA2 through
genetic or epigenetic events32;33. There is evidence that EOC cases with somatic BRCA1/2
mutations show a survival advantage over non-carriers33, but data from The Cancer Genome
Atlas and others suggest that silencing of BRCA1 through promoter methylation does not
result in an improved OS34;35. Larger studies that include comprehensive genomic screening
of BRCA1 and BRCA2 in primary EOCs will be needed determine if alterations at the
somatic and epigenetic level have similar clinical effects to germline mutations.
The results of this study have potentially important implications for the clinical management
of patients with EOC. Most immediately, our findings can be used by health care
professions for patient counseling regarding expected survival. BRCA1 and BRCA2 carriers
with EOC respond better than non carriers to platinum based chemotherapies, and have
improved survival despite the fact that the disease is generally diagnosed at a later stage and
higher grade. If patients could be stratified based on their BRCA status, their treatment
could be tailored to reflect this, with non-carriers targeted for more aggressive treatments.
Our data provide further support that there may be different functional mechanisms involved
in the etiology of different subtypes of EOCs, and therefore different therapeutic targets
based on germline and somatic genetic variation. For example, the functional
characterization of BRCA1 and BRCA2 led to the development of a novel therapy in
BRCA1/2 carriers based on inhibition of the poly (ADP-ribose) polymerase (PARP) DNA
repair pathway, creating a synthetic lethal phenotype. Recently, phase I and II trials have
shown anti-tumor activity of the PARP inhibitor Olparib in BRCA1/2 mutation carriers with
EOC15;36;37. These trials were not large enough to detect differences in response to Olparib
in BRCA1 vs. BRCA2 carriers and it is not known whether they will show similar levels of
response. EOC clinical trials should be stratified by BRCA status not only to more
appropriately target therapy but also to avoid the potential bias introduced by unequal
numbers of carriers in treatment arms or between study cohorts. Furthermore, given the
important prognostic information provided by BRCA1 and BRCA2 status and the potential
for personalized treatment in carriers, the routine testing of women presenting with high-
grade serous EOC may now be warranted.
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Figure 1. Kaplan Meier Estimates of Cumulative Survival According to BRCA1/2 status
Caption: Kaplan Meier analysis was adjusted for year of diagnosis and study.
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